Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions

D. H. Moon, J. M. Lee, A. M. Noonan, C. M. Annunziata, L. Minasian, N. Houston, J. L. Hays, E. C. Kohn

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

Background: We tested the hypothesis that BRCA1/2 mutation carriers with ovarian cancer are at higher risk of carboplatin hypersensitivity reactions (HSRs). Methods: Medical records of women enrolled in two carboplatin+olaparib clinical trials (NCT01237067/NCT01445418) were reviewed. A maximum of eight cycles containing carboplatin were administered. Results: All women (N=87) had good performance status and end-organ function. Incidences of carboplatin HSR before enrolment and on study were 17% and 21%, respectively. Most patients who developed carboplatin HSR had a deleterious BRCA1/2 mutation (93%) vs 50% in patients without HSR (P<0.0001). Multivariable analysis accounting for potential confounding variables including age, history of allergies, and cumulative prior carboplatin cycles confirmed deleterious BRCA1/2 mutation as an independent risk factor for carboplatin HSR (odds ratio 13.1 (95% confidence interval 2.6-65.4), P=0.0017). Mutation carriers had onset of carboplatin HSR at lower cumulative exposure (P=0.003). No significant difference in outcome was observed on our study between patients with and without a history of HSR. Conclusion: Deleterious BRCA1/2 mutation increased susceptibility and shortened time to carboplatin HSR, independently of other reported factors. These data suggest that at-risk women should be counselled regarding likelihood, symptoms, and potential earlier onset of carboplatin HSRs.

Original languageEnglish (US)
Pages (from-to)1072-1078
Number of pages7
JournalBritish Journal of Cancer
Volume109
Issue number4
DOIs
StatePublished - Aug 20 2013
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions'. Together they form a unique fingerprint.

  • Cite this

    Moon, D. H., Lee, J. M., Noonan, A. M., Annunziata, C. M., Minasian, L., Houston, N., Hays, J. L., & Kohn, E. C. (2013). Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. British Journal of Cancer, 109(4), 1072-1078. https://doi.org/10.1038/bjc.2013.389